Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT05799157 | Safety and Efficacy of VDMN-21 Patch in Subjects With Common Warts | PHASE2 | COMPLETED | 153 | — | — | Feb 28, 2023 | Feb 25, 2025 | May 8, 2025 | 16 | United States |
Complete clinical resolution is defined as the target lesion with area = 0.
| Arm | Type | Description |
|---|---|---|
| Treatment Group A (Low Dose) | EXPERIMENTAL | Low does patch will be applied adjacent to the target wart and remain in place for 5 minutes then removed. There may be up to 6 treatments (approximately 1 per month). |
| Treatment Group B (High Dose) | EXPERIMENTAL | High does patch will be applied adjacent to the target wart and remain in place for 5 minutes then removed. There may be up to 6 treatments (approximately 1 per month). |
| Treatment Group C (Vehicle) | PLACEBO_COMPARATOR | Vehicle patch will be applied adjacent to the target wart and remain in place for 5 minutes then removed. There may be up to 6 treatments (approximately 1 per month). |
| Name | Type | Description |
|---|---|---|
| VDMN-21 Patch Low Dose | DRUG | Microneedle patch containing 125 mcg of active drug |
| VDMN-21 Patch High Dose | DRUG | Microneedle patch containing 250 mcg of active drug |
| Vehicle Patch | DRUG | Placebo microneedle patch containing no active drug (i.e., placebo) |
Inclusion Criteria: * Subject is a male or non-pregnant female, 9 to 65 years of age. * Subject has provided written informed consent/assent. * Females must be post-menopausal, surgically sterile, or use an effective method of birth control. Women of childbearing potential (WOCBP) must have a negat...